With appearances at the 3rd Biotech Summit Austria in Graz (23–24 October 2025) and BIO-Europe 2025 in Vienna (3–5 November 2025), the Molecular Diagnostics Competence Unit of the AIT Austrian Institute of Technology has systematically expanded its visibility in the European biotech landscape. In Graz and Vienna, Martin Jung, Head of Competence Unit Molecular Diagnostics (HMD), and Andreas Weinhäusel, Deputy Head of HMD, used the events to position AIT’s systemic solution offerings in personalised medicine and health prevention in numerous discussions with companies and potential partners – including global big pharma players.
Systemic technology platforms in biotech and diagnostics
Biotech, pharma and diagnostics companies face the challenge of combining highly complex methods into a functional value chain that ranges from sample preparation and biomarker research through assay development to marketable diagnostic systems and point-of-care solutions. In practice, these steps are often organisationally and technically separated from one another, which delays the implementation of personalised, data-driven medicine.
Industry meetings such as the 3rd Biotech Summit Austria in Graz and BIO-Europe 2025 in Vienna address this very point. The Biotech Summit Austria brought together around 300 participants from 13 countries and provided an environment for exchange along the entire biotech value chain. BIO-Europe 2025 in Vienna is regarded as one of the leading European partnering conferences: over 6,000 participants from 65 countries, around 2,000 companies and more than 29,000 one-on-one meetings turned Vienna into a central hub for biopharmaceutical collaboration for three days.
Targeted partnering at international meetings
At the 3rd Biotech Summit Austria, AIT Molecular Diagnostics was represented with its own stand and specifically addressed partners in the field of preclinical research and personalised medicine. The focus was on discussions about collaborative projects in which preclinical research can be combined with innovative diagnostic approaches.
Two weeks later, AIT used BIO-Europe 2025 in Vienna to sharpen this profile in an international context. In around 30 partnering discussions with companies from Europe and beyond, solutions in the areas of preclinical research, personalised medicine and new diagnostic technologies were the focus. Noteworthy was the feedback from established industry leaders, who explicitly evaluated AIT’s systemic solution offering positively, thereby underlining the interest of globally active companies in the platforms of AIT Molecular Diagnostics.
“For many companies, it will be crucial not to view research, diagnostics and system solutions separately any longer,” says Martin Jung of AIT Molecular Diagnostics. “Formats such as the Biotech Summit Austria and BIO-Europe show that the demand is growing for partners who can cover platforms from biomarker discovery through to ready-to-use point-of-care systems.”
Deepening cooperation and integration into European networks
The presence in Graz and Vienna strengthens AIT’s position in the European biotech ecosystem as a partner that combines scientific excellence with industry-oriented, scalable solutions. In the coming months, AIT Molecular Diagnostics will systematically follow up on the contacts made at the conferences in order to develop concrete project ideas with industry and research partners and to integrate its own platforms in a targeted manner into European funding programmes.
In doing so, the Center for Health & Bioresources of the AIT Austrian Institute of Technology makes an important contribution to bringing diagnostic innovations more rapidly into clinical application and further advancing personalised, data-based healthcare in Europe.